Extract of Helicobacter pylori Ameliorates Parameters of Airway Inflammation and Goblet Cell Hyperplasia following Repeated Allergen Exposure

Background: An inverse relation between Helicobacter pylori infection and asthma has been shown in epidemiological studies. Infection with H. pylori, or application of an extract of it before or after sensitization, inhibits allergic airway disease in mice. Objectives: The aim of this study was to investigate the effect of an extract of H. pylori on allergic airway disease induced by repeated allergen exposure in mice that were sensitized and challenged prior to extract application. Method: C57BL/6 mice were intranasally (i.n.) sensitized and challenged with house dust mite (HDM). After a minimum of 4 weeks, mice received the H. pylori extract intraperitoneally and were rechallenged i.n. with HDM. Allergen-specific antibodies were measured by ELISA. Cells present in the bronchoalveolar lavage fluid and dendritic cell (DC) subsets in the lung tissue were analyzed by flow cytometry. Tissue inflammation and goblet cell hyperplasia were assessed by histology. Cells of the mediastinal lymph node (mLN) were isolated and in vitro restimulated with HDM or H. pylori extract. Results: Treatment with H. pylori extract before rechallenge reduced allergen-specific IgE, the DC numbers in the tissue, and goblet cell hyperplasia. Cells isolated from mLN of mice treated with the extract produced significantly more IL-10 and IL-17 after in vitro restimulation with HDM. mLN cells of H. pylori-treated mice that were re-exposed to the H. pylori extract produced significantly more interferon gamma. Conclusions: An extract of H. pylori is effective in reducing mucus production and various features of inflammation in HDM rechallenged mice.

[1]  C. Montón,et al.  A step‐down protocol for omalizumab treatment in oral corticosteroid‐dependent allergic asthma patients , 2018, British journal of clinical pharmacology.

[2]  H. Smits,et al.  Therapeutic Application of an Extract of Helicobacter pylori Ameliorates the Development of Allergic Airway Disease , 2018, The Journal of Immunology.

[3]  C. Powell,et al.  Anti-IL5 therapies for asthma. , 2017, The Cochrane database of systematic reviews.

[4]  C. Baena-Cagnani,et al.  Four-year follow-up in children with moderate/severe uncontrolled asthma after withdrawal of a 1-year omalizumab treatment , 2015, Current opinion in allergy and clinical immunology.

[5]  H. Kerstjens,et al.  Tiotropium attenuates IL-13-induced goblet cell metaplasia of human airway epithelial cells , 2015, Thorax.

[6]  C. Akdis,et al.  Regulatory T cells and immune regulation of allergic diseases: roles of IL-10 and TGF-β , 2014, Genes and Immunity.

[7]  Sebastian Reuter,et al.  Effective treatment of allergic airway inflammation with Helicobacter pylori immunomodulators requires BATF3-dependent dendritic cells and IL-10 , 2014, Proceedings of the National Academy of Sciences.

[8]  Guoxin Zhang,et al.  Association between Helicobacter pylori and asthma: a meta-analysis , 2013, European journal of gastroenterology & hepatology.

[9]  C. Taube,et al.  The role of Helicobacter pylori infection in the development of allergic asthma , 2012, Expert review of respiratory medicine.

[10]  P. Foster,et al.  Components of Streptococcus pneumoniae Suppress Allergic Airways Disease and NKT Cells by Inducing Regulatory T Cells , 2012, The Journal of Immunology.

[11]  S. Reuter,et al.  DC-derived IL-18 drives Treg differentiation, murine Helicobacter pylori-specific immune tolerance, and asthma protection. , 2012, The Journal of clinical investigation.

[12]  N. Glaichenhaus,et al.  The oral administration of bacterial extracts prevents asthma via the recruitment of regulatory T cells to the airways , 2011, Journal of Translational Medicine.

[13]  K. Mullane The increasing challenge of discovering asthma drugs. , 2011, Biochemical pharmacology.

[14]  B. Bošnjak,et al.  Treatment of allergic asthma: Modulation of Th2 cells and their responses , 2011, Respiratory research.

[15]  Sebastian Reuter,et al.  Helicobacter pylori infection prevents allergic asthma in mouse models through the induction of regulatory T cells. , 2011, The Journal of clinical investigation.

[16]  K. Rabe,et al.  IL-4 and IL-13 exposure during mucociliary differentiation of bronchial epithelial cells increases antimicrobial activity and expression of antimicrobial peptides , 2011, Respiratory research.

[17]  M. Kurrer,et al.  Bacterial-induced protection against allergic inflammation through a multicomponent immunoregulatory mechanism , 2011, Thorax.

[18]  J. Cazareth,et al.  The oral administration of bacterial extracts prevents asthma via the recruitment of regulatory T cells to the airways , 2011, Mucosal Immunology.

[19]  Henk C. Hoogsteden,et al.  Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells , 2008, The Journal of experimental medicine.

[20]  B. Vargaftig,et al.  Mycobacterium bovis BCG killed by extended freeze-drying reduces airway hyperresponsiveness in 2 animal models. , 2008, The Journal of allergy and clinical immunology.

[21]  C. Hawrylowicz Regulatory T cells and IL-10 in allergic inflammation , 2005, The Journal of experimental medicine.

[22]  C. Hawrylowicz,et al.  Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma , 2005, Nature Reviews Immunology.

[23]  E. Gelfand,et al.  The Role of IL-13 in Established Allergic Airway Disease1 , 2002, The Journal of Immunology.

[24]  D. Sheppard,et al.  Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma , 2002, Nature Medicine.

[25]  M. Mäkelä,et al.  Inhibition of phosphodiesterase 4 attenuates airway hyperresponsiveness and airway inflammation in a model of secondary allergen challenge. , 2001, American journal of respiratory and critical care medicine.

[26]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[27]  F. Mills,et al.  Activated mast cells produce interleukin 13 , 1995, The Journal of experimental medicine.